RE: Chat GPT14 Jan 2026 13:45
Kane
Have you read the RNS this increase is because of? It isn’t a sale or revenue it is just a development programme. So why is that worthy of a RNS but a new clinical trial, Gabriel, isn’t?
Showjumper did say his share of the year, “a 10 bagger” but if true acts in the same manner as IBAI then more likely to do small rises then drop back again.
I am still unsure why:
a) TB sold his holding to BRH, in theory he now only owns 9% of IBAI
b) why IBAI bought Kirkstall, was it to just pay for this development programme by paraytec?
The joys of being an IBAI shareholder
Thanks